Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma

Dr. faraidwn habib mustafa
Dr. faraidwn habib mustafa * §
Contact
§ Hawler Medical University

Send Message

To: Author

Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma

Article Fingerprint

ReserarchID

MRIGNN0

Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
Access Review Comments
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background

References

204 Cites in Article
  1. S Abrams (2001). Chronic Pulmonary Insufficiency in Children and Its Effects on Growth and Development.
  2. F Afridi,S Ahmad,K Hassan,M Jaffery,N Ikram,H Qureshi (1998). An etiological factor of bronchial asthma in a rural area of upper Punjab.
  3. A Alsamarai,A Alwan,A Ahmad,M Salih,J Salih,M Aldabagh,S Alturaihi (2009). The Relationship between Asthma and Allergic Rhinitis in the Iraqi Population.
  4. American Thoracic,Society Statement (1991). Lung Function Testing: Selection of Reference Values and Interpretative Strategies.
  5. American Thoracic,Society (1995). Standardization of spirometry. Update.
  6. Anon (1998). Singulair (montelukast)--Possible Association Between Use of Singulair and Behavior/Mood Changes, Suicidality, and Suicide.
  7. Xiang-Ping Zeng (1999). Pharmacology of some new anti-asthma drugs : potassium channel opening drugs and platelet-activating factor antagonists.
  8. Anon (2003). Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture.
  9. Anon (1992). Asthma: a follow up statement from an international paediatric asthma consensus group..
  10. Anonymous (1998). Third international Pediatric Consensus Statement on the Management of Childhood Asthma.
  11. S Balani,X Xu,V Pratha (1997). Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
  12. A Barbier,M Bradbury (2007). Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders.
  13. L Barclay (2005). Montelukast in intermittent mild asthma.
  14. P Barnes (2000). Unknown Title.
  15. P Barnes (2002). Cytokine modulators as novel therapies for asthma.
  16. N Barnes,P Piper,J Costello (1984). Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects..
  17. David Aharony (1998). Pharmacology of Leukotriene Receptor Antagonists.
  18. P Barnett,G Caputo,M Baskin,N Kuppermann (1997). Intravenous versus oral corticosteroids in the management of acute asthma in children.
  19. Jc ; Alexander,E Bateman,S Hurd,P Barnes,J Bousquet,J Drazen,M Fitzgerald,P Gibson,K Ohta,O' Byrne,P Pedersen,S Pizzichini,E,S Sullivan,S Wenzel,S Zar,H (2005). “Global strategy for asthma management and prevention: GINA executive summary.” E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel and H.J. Zar.<i>Eur Respir J</i>2008; 31: 143–178..
  20. R Beasley (2002). The burden of asthma with specific reference to the United States.
  21. Allan Becker,Arlene Swern,Carol Tozzi,Qinfen Yu,Theodore Reiss,Barbara Knorr (2004). Montelukast in asthmatic patients 6 years–14 years old with an FEV<sub>1</sub>> 75%.
  22. A Becker,O Kuznetsova,J Vermeulen,E Manuel,Betty Soto-Quiros,Young,F Reiss,S Dass,B Knorr (2006). Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized.
  23. R Behrman,R Kliegman,H Jenson (2003). Nelson Textbook of Pediatrics.
  24. N Beydon,I Pin,R Matran,M Chaussain (2003). Pulmonary function tests in preschool children with asthma.
  25. H Bisgaard,Zielen -S,Garcia Garcia,M Johnston,S Gilles,L Menten,J Tozzi,C Polos,P (2004). Unknown Title.
  26. Hans Bisgaard,Stefen Zielen,María Garcia-Garcia,Sebastian Johnston,Leen Gilles,Joris Menten,Carol Tozzi,Peter Polos (2005). Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old Children with Intermittent Asthma.
  27. Hans Bisgaard,David Skoner,Maria Boza,Carol Tozzi,Kathleen Newcomb,Theodore Reiss,Barbara Knorr,Gertrude Noonan (2009). Safety and tolerability of montelukast in placebo‐controlled pediatric studies and their open‐label extensions.
  28. Jean Bousquet,Peter Jeffery,William Busse,Malcolm Johnson,Antonio Vignola (2000). Asthma.
  29. J Boyce (2003). Mast cells: beyond IgE.
  30. Katie Bradley (2009). Blueprints PEDIATRICS.
  31. C Bradley (2004). Targeted anti-IgE Therapy for Patients With Moderate to Severe Asthma.
  32. J Brandes,W Visser,M Farmer (2004). Montelukast for migraine prophylaxis: a patients with asthma of differing severity.
  33. (2003). British guideline on the management of asthma.
  34. U Broberger,V Graff‐lonnevig,G Lilja,E Rylander (1985). Ketotifen in pollen‐induced asthma: a double blind placebo‐controlled study.
  35. Gertrud Brunlöf,Carina Tukukino,Susanna Wallerstedt (2008). Individual case safety reports in children in commonly used drug groups – signal detection.
  36. William Busse,Robert Lemanske (2001). Asthma.
  37. William Busse,William Calhoun,Julie Sedgwick (1993). Mechanism of Airway Inflammation in Asthma.
  38. (2007). BTS/NICE/SIGN joint guideline on asthma: diagnosis, monitoring and chronic asthma management (November 2024) - summary of recommendations.
  39. A Butch,T Goodnow,W Brown,A Mcclellan,G Kessler,M Scott (1989). Stratus automated creatine kinase-MB assay evaluated: identification and elimination of falsely increased results associated with a high-molecular-mass form of alkaline phosphatase..
  40. Chang Cai,Jiong Yang,Suping Hu,Meiqian Zhou,Wei Guo (2006). Relationship Between Urinary Cysteinyl Leukotriene E4 Levels and Clinical Response to Antileukotriene Treatment in Patients with Asthma.
  41. C Calpin,C Macarthur,D Stephens,W Feldman,P Parkin (1997). Effectiveness of Prophylactic inhaled steroids in childhood asthma: a systemic review of the literature.
  42. G Canny,J Reisman,H Levison (1997). Does ketotifen have a steroid-sparing effect in childhood asthma?.
  43. L Caps (1991). Immunologic and therapeutic aspects of ketotifen.
  44. V Capra,M Ambrosio,G Riccioni,G Rovati (2006). Cysteinyl-Leukotriene Receptor Antagonists: Present Situation and Future Opportunities.
  45. Valérie Capra,Miles Thompson,Angelo Sala,David Cole,Giancarlo Folco,G Rovati (2007). Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends.
  46. John Carl,Timothy Myers,H Kirchner,Carolyn Kercsmar (2003). Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
  47. C Brindicci,K Ito,P Barnes,Sa ; Kharitonov,I Carlos,S Sidney,E Lydick,Michael Sorel,D Mark (2001). The association between asthma, asthma therapeutic classes and hepatic enzyme elevation among adult HMO members.
  48. E Carlos,Leonard Baena-Cagnani (2010). Lung function measurement in the assessment of childhood asthma: recent important developments.
  49. W Carr,L Zeitel,K Weiss (1992). Variations in asthma hospitalizations and deaths in New York City..
  50. Thomas Casale,Michael Blaiss,Erwin Gelfand,Timothy Gilmore,Philip Harvey,Ian Hindmarch,F Simons,Dennis Spangler,Stanley Szefler,Thomas Terndrup,Scott Waldman,John Weiler,Dean Wong (2003). First do no harm: Managing antihistamine impairment in patients with allergic rhinitis.
  51. G Castillo,M Sanz,P Gamboa,A Oehling (1987). IgE receptors and serum IgE in pollinosis. The influence of season and action of ketotifen.
  52. J Castillo,A Oehling,P Gamboa (1991). Mechanism of ketotifen action in hypersensitivity reactions. Its effect on cellular enzymatic activities.
  53. José Castro-Rodríguez,Catharine Holberg,Anne Wright,Fernando Martinez (2000). A Clinical Index to Define Risk of Asthma in Young Children with Recurrent Wheezing.
  54. C Cates,A Bara,J Crilly,B Rowe (2003). Holding chambers versus nebulisers for beta-agonist treatment of acute asthma.
  55. J Catterall,Pma Calverley,J Power,C Shapiro,N Douglas,D Flenley (1983). Ketotifen and nocturnal asthma..
  56. G Chalmers,K Macleod,S Little,L Thomson,C Mcsharry,N Thomson (2002). Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma.
  57. Susana Ch??vez-Bueno,Asunci??n Mej??as,Robert Welliver (2006). Respiratory Syncytial Virus Bronchiolitis.
  58. H Cheng,J Leff,R Amin (1996). Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
  59. Shuei‐tu Chen,Ko‐hsiu Lu,Hai‐lun Sun,Wen‐tung Chang,Ko‐huang Lue,Ming‐chih Chou (2006). Randomized placebo‐controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr.
  60. M Chiba,X Xu,J Nishime,S Balani,J Lin (1997). Hepatic microsomal metabolism of IgE and Eosinophils in Respiratory Allergy Patients.
  61. M Church,M Maurer,Fer Simons,C Bindslev-Jensen,J Cauwenberge,Bousquet (2010). Risk of first-generation H1 antihistamines: a GA2LEN position paper.
  62. Lauren Cohn,Jack Elias,Geoffrey Chupp (2004). A <scp>sthma</scp> : Mechanisms of Disease Persistence and Progression.
  63. Milton Cohen,R Weller,S Cohen (1940). ANTHROPOMETRY IN CHILDREN.
  64. W Cookson,M Moffatt (2000). Genetics of asthma and allergic disease.
  65. Jonathan Corne,Clare Marshall,Sandra Smith,Jacquie Schreiber,Gwendolyn Sanderson,Stephen Holgate,Sebastian Johnston (2002). Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study.
  66. C Cowan,R Neville,G Thomas,I Crombie,R Clark,I Ricketts (1998). Effect of asthma and its treatment on growth: four year follow-up of cohort of children from general practices in Taysid, Scotland.
  67. H Crampton (2003). Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
  68. J Croce,E Negreiros,J Mazzei,G Isturiz (1995). A double‐blind, placebo‐controlled comparison of sodium cromoglycate and ketotifen in the treatment of childhood asthma.
  69. Kati Hagström,Outi Saarenpää-Heikkilä,Sari-Leena Himanen,Anna-Maria Lapinlampi,Pirkko Nieminen (2001). Behavioral Problems and Neurocognitive Functioning in Snoring School-Aged Children.
  70. B Davis (2009). Protective effect of histamine 1 and cyslt1 antagonist on allergen induced airway responses in atopic asthma.
  71. O Dempsey (2000). Leukotriene receptor antagonist therapy.
  72. B Chipps (2004). Use of ketotifen in asthma.
  73. E Chowdary,J Vinaykumar,Ratna Rao,K Rao,G Diette,J Krishnan,L Wolfenden,E Skinner,D Steinwachs,A Wu (2004). Relationship of physician estimate of underlying asthma severity to asthma outcomes.
  74. Di Lorenzo,G Mansuetop,M Melluso,G Morici,Ram Babu,V Rangamani,; Esposito Pellitteri,M (1997). Nonspecific airway hyperresponsiveness in monosensitive sialian patients with allergic rhinitis: Its relationship to total serum IgE level and blood eosinophils during and out of the pollen season.
  75. A Ditto,J Krasnick,P Greenberger,K Kelly,K Mcgrath,R Patterson (1997). Pediatric idiopathic anaphylaxis: experience with22 patients.
  76. R Dockhorn,R Baumgartner,J Leff (2000). Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients.
  77. J Drazen,Austen Kf (1999). Leukotrienes and airway responses.
  78. M Dukes,J Aronson (2000). Meyler's Side Effects of Drugs.
  79. Francine Ducharme,Franco Di Salvio (2004). Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
  80. M Edmonds,C Camargo,Jr,C Pollack,Jr,B Rowe (2004). Early use of inhaled corticosteroids in the emergency department treatment of acute asthma.
  81. M Emanuel (1999). Histamine and the antiallergic antihistamines: a history of their discoveries.
  82. Paul Enright,Michael Lebowitz,Donald Cockroft (1994). Physiologic Measures: Pulmonary Function Tests.
  83. J Evans (2002). Cysteinyl leukotriene receptors.
  84. J Fahy (2000). Reducing IgE levels as a strategy for the treatment of asthma.
  85. A Fall,A Kopec (2010). Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment.
  86. R Floud,K Wachter,A Gregory (1990). Height, health and history: nutritional stature in the United Kingdom, 1750-1980.
  87. W Fokkens,Gk ; Scadding,A Gennaro,C Carnini,C Buccellati,R Ballerio,S Zarini,F Fumagalli (2004). Perennial rhinitis in the under 4s: A difficult problem to treat safely and effectively. A comparison of intranasal fluticasone propionate and ketotifen in the treatment 93.
  88. James Gern,Claudia Reardon,Sabine Hoffjan,Dan Nicolae,Zhanhai Li,Kathy Roberg,William Neaville,Kirstin Carlson-Dakes,Kiva Adler,Rebekah Hamilton,Elizabeth Anderson,Stephanie Gilbertson-White,Christopher Tisler,Douglas Dasilva,Kelly Anklam,Lance Mikus,Louis Rosenthal,Carole Ober,Ronald Gangnon,Robert Lemanske (2004). Effects of dog ownership and genotype on immune development and atopy in infancy.
  89. Elizabeth Hill,Roshani Patel,Arnold Bolomsky,Ryan Young (2003). Unlocking Precision Medicine in Multiple Myeloma: Venetoclax and Novel Targeted Therapies.
  90. Gina (2006). The global Initiative for Asthma Report: Global Strategy for Asthma Management & Prevention.
  91. M Giudice,A Pezzulo,C Capristo,E Alterio,S Caggiano,D Benedictis,A Capristo (2009). Leukotriene modifiers in the treatment of asthma in children.
  92. (1995). Management Segment. Chapter seven.
  93. M Goldstein,J Anoia,B Black M ; Dahlström,B Lindström (1992). Pharmacokinetics of ketotiffn after oral administration to healthy male subjects.
  94. S Grant,K Goa,A Fitton,E Sorkin (1990). Ketotifen A review of its pharmacodynamic and Pharmacokinetic properties and therapeutic use in asthma and allergic disorders.
  95. C Groggins,E Hiller,A Milner,G Stokes (1981). Ketotifen in the prophylaxis of childhood asthma.
  96. T Guilbert,W Morgan,R Zeiger,D Mauger,S Boehmer,S Szefler (2006). Long term of 2-4-year-old children with perennial rhinitis.
  97. M Garcia,U Wahn,L Gilles,A Swern,C Tozzi,Polos P ; Pm,L Watson,K Davis,K Rabe,K Harmanci,R,Susanne Alexander,F (1977). Montelukas tcompared with fluticasone, control of asthma among 6 to 14 year old patients with mild asthma: The MOSAIC study.
  98. Henderson Wr (1994). Role of leukotrienes in asthma.
  99. A Henderson,D Moss,T Enzyme (2000). Fundamental of Clinical Chemistry.
  100. C Ashwood,E Saunder,L Herbarth,U Suttmann,M Ballmaier,F Rohde,H Deicher,I ; Schedel,J Holloway,G Koppelman (1993). Effects of ketotifen on HIV infected individuals International Conference on AIDS.
  101. S Holgate,G Canonica,F Simons,M Taglialatela,M Tharp,H Timmerman,K Yanai (2003). Consensus group on new‐generation antihistamines (CONGA): present status and recommendations.
  102. Stephen Holgate,Thomas Casale,Sally Wenzel,Jean Bousquet,Yamo Deniz,Colin Reisner (1975). The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
  103. Randy Horwitz,Kelly Mcgill,William Busse (1998). The Role of Leukotriene Modifiers in the Treatment of Asthma.
  104. Faruk Incecik,Yusuf Onlen,Ozlem Sangun,Sabahat Akoglu (2007). Probable montelukast-induced hepatotoxicity in a pediatric patient : Case report.
  105. W John,Sons (2004). Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children.
  106. Jonathan,Spergel (2010). Epidemiology of Atopic Dermatitis and Atopic March in Children.
  107. Sushil Kabra,Ravindra Pandey,Rajveer Singh,Vimlesh Seth (2000). Ketotifen for asthma in children aged 5 to 15 years: a randomized placebo-controlled trial.
  108. S Kharitonov,K Alving,P Barnes,M J ; Kilpelainen,E Terho,H Helenius,M ; Koskenvuo,M Kilpelainen,E Terho,H Helenius,M Koskenvuo (1997). Exhaled and nasal nitric oxide measurements: recommendations.The European Respiratory Society Task Force.
  109. B Knorr,L Franchi,H Bisgaard,J Vermeulen,Le Souef,P Santanello,N (2001). Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2 to 5 years.
  110. B Knorr,H Nguyen,G Kearns (2001). Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults.
  111. Blair Jarvis,Anthony Markham (2000). Montelukast.
  112. B Knorr,G Noonan,H Nguyen,T Reiss,T Michele,M Sota,L Franchi,O Aldrey,J Haltom,D Atkinson,W Berger,D Bratton,R Urruela (2000). 69 Evaluation of the safety profile of montelukast (MK-0476) in pediatric patients aged 2 to 5 years.
  113. B Knorr,P Larson,H Nguyen (1999). Montelukast dose selection in 6-to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults.
  114. B Knorr (1998). Montelukast for chronic asthma in 6to 14-year-old children. A randomized double-blind trial.
  115. B Knorr,A Kozyrskyj,A Becker (2000). Early life exposure to antibiotics for non-respiratory infections is associated with asthma.
  116. M ; Kurosawa,J Lagos,Gd ; Marshall,A Laitinen,A Lindqvist,M Halme,A Altraja,L Laitinen (1990). Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
  117. Alessandro Lambiase,S Bonini,G Rasi,M Coassin,A Bruscolini,S ; Lemnaske Rf Bonini,Jr,D Jackson,R Gangnon (2003). Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma.
  118. H ; Levison,M Levy,M Fletcher,D Price,T Hausen,R Halbert,Bp ; Yawn,B Lipworth (1991). Respiratory Group (IPCRG). Guidelines: diagnosis of respiratory diseases in primary care.
  119. A Liu,J Spahn,D Leung,M Pettersen,M Granum,B Lovik,M Carlson,Kh ; Malo,J,Chan-Yeung M (2004). Asthma in every fifth child in Oslo, Norway: a 10-year follow up of a birth cohort study.
  120. Partam Manalai,Jong-Min Woo,Teodor Postolache (2009). Suicidality and montelukast.
  121. F Marc,James Goldstein,B ; Martin,F Marra,L Lynd,M Coombes (1993). The pharmacological properties of a new orally active antianaphylactic compound: Ketotifen a benzocyclo heptatiophen.
  122. A Martin,L Landau,P Phelan (1981). The effect on growth of childhood asthma.
  123. F Martinez,A Wright,L Taussig,C Holberg,M Halonen,Morgan Wj ; M Fabian,D Holt,S Beasley,R ; Mastalerz,L Kumik,J (1995). The global burden of asthma: executive summary of the GINA Dissemination Committee report.
  124. Leonardo Mata,Juan Urrutia,Aaron Lechtig (1971). Infection and nutrition of children of a low socioeconomic rural community.
  125. L Mcfadyen,R Miller,Tm ; Ludden,; Z Mehta,L Grummer-Strawn,A Pietrobelli,A Goulding,M Goran,W Dietz (1997). Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents.
  126. Katie Meyer,Jean Arduino,Nancy Santanello,Barbara Knorr,Hans Bisgaard (2003). Response to montelukast among subgroups of children aged 2 to 14 years with asthma.
  127. E Migoya,G Kearns,A Hartford (2004). Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old.
  128. Henry Milgrom,Bruce Bender,Lynn Ackerson,Pamela Bowrya,Bernita Smith,Cynthia Rand (1996). Noncompliance and treatment failure in children with asthma.
  129. H Mita,M Hasegawa,H Saito,K ; Akiyama (1995). Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils.
  130. A Mitra,D Bassler,F Ducharme (2004). Intravenous aminophylline for acute severe asthma in children over 2 years using inhaled bronchodilators.
  131. Mohammad Ehlayel,B Abdulbari (2008). Montelukast use in atopic dermatitis has been evaluated in many clinical trials.
  132. Robert Monie,A Smith,David Leopold,Gerald Anderson,Brian Davies,Gordon Thomas (1982). A double-blind clinical trial of ketotifen and disodium cromoglycate in bronchial asthma.
  133. J Montplaisir,J Walsh,J Malo (1982). Nocturnal Asthma: Sleep and Dream Analysis.
  134. M Morita,S Tsuruta,K Mori,M Mayumi,H Mikawa (1990). Ketotifen inhibits PAF-induced actin polymerization in a human eosinophilic leukaemia cell line, EoL-1.
  135. M Movahedy (2000). Asthma, prevention, diagnosis and treatment for general physicians.
  136. S Mucha,M Naclerio,R Baroody,Fm ; Munoz,N Douglas,I Mayer,D Herrnreiter,A Zhu,X Leff,Ar ; Murray,A Morrison,B (1989). Passive smoking by asthmatics: its greater effect on boys than on girls and older than on younger children.
  137. K Naomi,K Toshio,O Yasuhei,M A Akihiro (2006). Randomized Open-Label Comparative Study of Montelukast versus Theophylline Added to Inhaled Corticosteroid in Asthmatic Children.
  138. M Nematia,B Habibi,Asld,K Sharifia (2006). Effect of Ketotifen and Cyproheptadine on Appetite and Weight Changes in Mice.
  139. R Neville,C Mccowan,G Thomas,I Crombie,Asthma & Growth In Tayside Children (1996). Ashma and growth—Cause for concern?.
  140. S Nicosia,V Capra,G Rovati (2001). Leukotrienes as Mediators of Asthma.
  141. Sankei Nishima,Kenshi Furusho,Akihiro Morikawa,Hiroyuki Mochizuki,Toru Akasaka,Hideo Sugimoto,Toshiichi Ikebe,Toshiyuki Nishimuta,Kunio Sekine,Masanori Yamada,Hiroshi Odajima,Chikako Motomura,Atsushi Yamatodani (2005). Pranlukast Inhibits Exercise-Induced Bronchospasm in Asthmatic Children: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Two-Period Crossover Trial.
  142. M Noonan,P Chervinsky,M Brandon,J Zhang,S Kundu,J Mcburney,T Reiss (1998). Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.
  143. Masako Nozaki,Masanobu Yoshikawa,Kunihiko Ishitani,Hiroyuki Kobayashi,Kiyohiro Houkin,Kohzoh Imai,Yoichiro Ito,Takamura Muraki (2010). Cysteinyl Leukotriene Receptor Antagonists Inhibit Tumor Metastasis by Inhibiting Capillary Permeability.
  144. Helena Nyblom,Einar Björnsson,Magnus Simrén,Frank Aldenborg,Sven Almer,Rolf Olsson (1997). The AST/ALT ratio as an indicator of cirrhosis in patients with PBC.
  145. J Ockenga,F Rohde,U Süttmann,L Herbarth,M Ballmaier,I Schedel (1996). Ketotifen in HIV-infected patients: effects on body weight and release of TNF-α.
  146. Nobuyuki Okamura,Kazuhiko Yanai,Makoto Higuchi,Jun Sakai,Ren Iwata,Tatsuo Ido,Hidetada Sasaki,Takehiko Watanabe,Masatoshi Itoh (2000). Functional neuroimaging of cognition impaired by a classical antihistamine, <i>d</i>‐chlorpheniramine.
  147. R Oriol,S Gómez-Ollés,Maria Jesús,C Xavier,M Mark,J,Joan Rm (2008). Effects of salbutamol on exhaled breath condensate biomarkers in acute lung injury: prospective analysis.
  148. J Owen,A Dempsey,J Wilson (2000). Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled.
  149. D ; Paige,M Fernandez,S Garcia-Rubia,M Sanchez-Solis,L Garcia-Marcos (1998). Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children.
  150. K ; Parafitt,W Pardridge (1999). Blood-brain barrier biology and methodology.
  151. S Patil,Y Pore,B Kuchekar,A Manei,Khire Vg ; Profeta,Sc ; Fernandez,H,Garcia-Rubia (2003). Montelukast administered in the morning or in the evening to prevent exercise induced bronchoconstriction in children.
  152. R Pellegrino,G Viegi,V Brusasco,R Crapo,F Burgos,R Casaburi,A Coates,C Van Der Grinten,P Gustafsson,J Hankinson,R Jensen,D Johnson,N Macintyre,R Mckay,M Miller,D Navajas,O Pedersen,J Wanger (2005). Interpretative strategies for lung function tests.
  153. B Pennock,J Cottrell,Rm ; Rodgers,M Peters-Golden,J W R Henderson (1983). Pulmonary function testing.
  154. P J Phillips,A E Vedig,P L Jones,M Chapman,M Collins,J Edwards,T Smeaton,B Duncan (1980). Metabolic and cardiovascular side effects of the beta 2‐adrenoceptor agonists salbutamol and rimiterol..
  155. G Philip,K Malmstrom,F Hampel,S Weinstein,C Laforce,P Ratner,M Malice,T Reiss (2002). Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring.
  156. G Polgar,T R ; Weng,M Preece,C Law,Psw ; Davies,D Price (1979). The Functional Development of Respiratory System-From Period Of Gestation To Adulthood.
  157. Teet Pullerits,Lea Praks,Bengt-Eric Skoogh,Raivo Ani,Jan Lötvall (1999). Randomized Placebo-controlled Study Comparing a Leukotriene Receptor Antagonist and a Nasal Glucocorticoid in Seasonal Allergic Rhinitis.
  158. Teet Pullerits,Lea Praks,Vahur Ristioja,Jan Lötvall (2002). Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
  159. I Quack,L Sellin,N Buchner,D Theegarten,L Rump,B Henning,K Rabe,D Schmidt (2001). Eosinophilic gastroenteritis in a young girl-long term remission under montelukast.
  160. A Rackham,C Brown,R Chandra,P Ho,P Hoogerwerf,R Kennedy,A Knight,H Langer,J Milne,D Moote (1989). A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years.
  161. K Rance,C Trent (2005). Profile of a primary care practice asthma program: Improved patient outcomes in a high-risk population.
  162. C Ramsay,C Van Kan,R Nieman,J Wang,Jhjm Van Krieken,Lna Willems (1997). The effects of oral pranlukast on airway immunopathology and clinical parameters in patients with asthma.
  163. J Reinus,S Persky,J Burkiewicz,D Quan,N Bass,T Davern (2000). Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast.
  164. G Riccioni,F Santilli,N D'orazio,S Sensi,R Spoltore,M De Benedictis,M Guagnano,C Di Ilio,C Schiavone,E Ballone,R Della Vecchia (2002). The Role of Antileukotrienes in the Treatment of Asthma.
  165. B Rowe,C Spooner,F Ducharme,J Bretzlaff,G Bota (2004). Early emergency department treatment of acute asthma with systemic Global Journal of Medical Research Volume XII Issue X Version I ear 2012 Y Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma corticosteroids.
  166. S Sanada,T Tanaka,Y Kameyoshi,M Hide (2005). The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.
  167. Sarah,Corathers (2006). Focus on Diagnosis: The Alkaline Phosphatase Level: Nuances of a Familiar Test.
  168. Michael Schatz,Carlos Camargo (2003). The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization.
  169. J Scherwin (2003). Liver function Clinical Chemistry: Theory,Analysis, Correlation.
  170. Ed Kaplan,L Pesce,A Kazmierczak,S Schmitt-Grohé,S Eickmeier,O Schubert,R Bez,C Zielen,; Schoors,D,De Smet,M Reiss,T ; Schoch,C (1995). Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4 receptor antagonist, in healthy volunteers.
  171. G Schwartzer,D Bassler,Mitra Duchame,F Forster,J (2004). Ketotifen alone or as additional medication for longterm control of asthma and wheeze in children.
  172. K Shakya,P Joshi,A Piya,Mir Baral (2003). Efficacy and tolerability of Ketotifen in Nepalese asthmatic children.
  173. Shields,Brown,Stevenson,Fitch,Schock,Turner,Taylor,Ennis (1999). Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing.
  174. M Silverman,N Wilson;,N Speight (1997). Asthma---time for a change of name? Commentary.
  175. F Simons,J Villa,B Lee,A Teper,B Lyttle,G Aristizabal (1985). Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.
  176. D Solé,A Spiniola-Castro,O Denardim,L Anuda,M Mallozi,C Naspitz (1991). 1. GROWTH HORMINE (CH) LEVELS IN ALLERGIC CHILDREN BEFORE AND AFTER SLANDARDZED EXERCISE.
  177. R Sporik,J Ingram,W Price,J Sussman,R Honsinger,T Platts-Mills (2001). Association of asthma with serum IgE and skin test reactivity to allergens among children living at high.
  178. Elisabeth Ståhl,Dirkje Postma,Klas Svensson,Anne Tattersfield,Arne Eivindson,Ad Schreurs,Claes-Göran Löfdahl (2003). Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids.
  179. I Stelmach,J Jerzynska,Pa Kuna,I Stelmach,A Korzeniewska,K Smejda,I Jarosz,W Stelmach (2002). Randomized double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1(sICAM-1) in children with asthma.
  180. David Strachan,Barbara Butland,H Anderson (1996). Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort.
  181. J Sundell,B Kolarik,K Naydenov,M Larsson,H Engman,C Bornehag (2006). Asthma and allergies: The role of the home environment.
  182. J Sunyer,J Anto,M Kogevinas,M Barcelo,J Soriano,A Tobias,N Muniozguren,J Martinez-Moratalla,F Payo,J Maldonado (1997). Risk factors for asthma in young adults. Spanish Group of the European Community Respiratory Health Survey.
  183. Cecilie Svanes,Deborah Jarvis,Susan Chinn,Peter Burney (1999). Childhood environment and adult atopy: Results from the European Community Respiratory Health Survey.
  184. A Tattersfield,A Knox,J Britton,I Hall (2002). Asthma.
  185. E Tepas,Dt ; Umetsu,Thomson (2000). Long-term effects of budesonide or nedocromil in children with asthma.
  186. K Toshiyuki,F Masaki,O Haruhiko,N Yasuto,N Satoshi,I Yoshihisa (2010). Antitussive Effects of the Leukotriene Receptor Antagonist Montelukast in Patients with Cough Variant Asthma and Atopic.
  187. Andrew Travers,Arthur Jones,Karen Kelly,Carlos Camargo,Samantha Barker,Brian Rowe (2004). Intravenous beta2-agonists for acute asthma in the emergency department.
  188. E Tug,U Ozbey,T Tug,H ; Yuce,S Demirsoy,E Koç,N Gökçora,S ; Elbeg,P Uyan,A Gozukara (1996). Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma.
  189. U (1992). International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992.
  190. J Van Adelsberg,J Moy,L Wei,C Tozzi,B Knorr,T Reiss,J Vandervoode,S Verbanck,D Schuermans,L Broekaert,D Devroey,J Kartounian,W ; Vincken,A Verberne,C Frost,R Roorda,H Van Der Laag,K Kerrebijn (1997). One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.
  191. Benjamin Volovitz,Isaac Varsano,James Cumella,Lutfi Jaber (1988). Efficacy and safety of ketotifen in young children with asthma.
  192. Mandeep Walia,Rakesh Lodha,S Kabra (2006). Montelukast in pediatric asthma management.
  193. S Walker,A Sheik (2002). Unknown Title.
  194. S Wallerstedt,G Brunlöf,A Sundström,Al ; Eriksson,Oj ; Warner,J Weiss (1983). Airway constriction in normal human produced by inhalation of leukoterine D. potency, time course, & effect of aspirin therapy.
  195. S Wenzel,S Wenezel,J Wiess (1982). Bronchoconstrictor effects of leukoterine C in human bronchi.
  196. K Wickens,J Lane,P Fitzharris,R Siebers,G Riley,J Douwes,T Smith,J Crane (2002). Farm residence and exposures and the risk of allergic diseases in New Zealand children.
  197. A Wiqar,Altaf Shaikh,Patel,S Kamal,Rajat Saini,Kiran Saha,Chulki (2008). management of allergy and asthma.
  198. Nicholas Withers,Lorraine Low,Stephen Holgate,Joanne Clough (1998). The Natural History of Respiratory Symptoms in a Cohort of Adolescents.
  199. N Yagi,Y Taniuch,K Hamada,J Sudo,H Sekikawa (2002). Pharmacokinetics of ketotifen fumarate after intravenous, intranasal, oral and rectal administration in rabbits.
  200. K Yanai,J Ryu,T Watanabe,R Iwata,T Ido,M Asakura,R Matsumura,M Itoh (1995). Positronemission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a secondgeneration antihistamine.
  201. K Yanai,N Okamura,M Tagawa,M Itoh,T Watanabe (1999). New findings in pharmacological effects induced by antihistamines: from PET studies to knock‐out mice.
  202. Maria Yazdanbakhsh,Sitti Wahyuni (2005). The role of helminth infections in protection from atopic disorders.
  203. J Zambrano,H Carper,G Rakes,J Patrie,D Murphy,T Platts-Mills,J Gwaltney,Jr,T Hatley,A Owens,P Heymann (2003). Experimental rhinovirus challenges in adults with mild asthma: Response to infection in relation to IgE.
  204. Jamie Zhao,J Rogers,Sherry Holland,Patrick Larson,Raju Amin,Rita Haesen,Amanda Freeman,M Seiberling,M Merz,Haiyung Cheng (1997). Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.
Show All References
Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Dr. faraidwn habib mustafa. 1970. "Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma". Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 12 (GJMR Volume 12 Issue B10).

More Citation Formats

Download Citation

  • Open Access
  • CC-BY-ND-NC 4.0
Download Article
Access OJS
Journal Specifications

Crossref Journal DOI 10.17406/gjmr

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Asthma Managementeosinophilshyperresponsivenessmedication
Classification
GJMR-B Classification FOR Code: 110203
920115
730110 NLMC Code WD 300
WF 553
  • Submission ReceivedNovember 4, 2012
  • Peer Review Double Blind
    Handling Editor
  • Accepted November 27, 2012
  • Published December 8, 2012
Version of record

v1.2

Language
English
Order Article Reprint
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR
Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D
Article Matrices
Total Views: 7.6K
Total Downloads: 538
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Therapeutic and Some Biochemical Studies of Montelukast and Ketotifen of Children with Mild Asthma

Dr. mustafa
Dr. mustafa Hawler Medical University
  • Submission ReceivedNovember 4, 2012
  • Peer Review Double Blind
    Handling Editor
  • Accepted November 27, 2012
  • Published December 8, 2012